ViaCyte Raises $80M

San Diego-based biotech startup ViaCyte, which is developing human cell therapy for treating diabetes, says it has raised $80M in a Series D funding round. The funding was led by Bain Capital Life Sciences, and also included TPG, RA Capital Management, Sanderling Ventures, plus angels. According to the company, the funding will go to advance its stem cell tech.